SCHEMBL4437360

SCHEMBL4437360

O=C(O)c1cccn(Cc2ccc(Br)cc2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.56
BRD2 P25440 1/20 0.56
BRD3 Q15059 1/20 0.56
BRDT Q58F21 1/20 0.56
HDAC3 O15379 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 1/20 0.55
RAB9A P51151 1/20 0.55
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137531 0.87 BRD4 (0.70) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4990876 0.87 BRD4 (0.51) BRD4BRD2BRD3BRDTHDAC3
SCHEMBL2621620 0.86 CNR1 (0.60) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL6524399 0.86 VEGFA (0.65) BRD4BRD2BRD3BRDTSMN1; SMN2
Hydrochloric Acid SCHEMBL11454825 0.86 BRD4 (0.68) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL19787909 0.85 MAPT (0.60) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4993019 0.85 BRD4 (0.59) BRD4BRD2BRD3BRDTHDAC8
SCHEMBL4992892 0.85 BRD4 (0.68) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4993820 0.84 HDAC3 (0.58) BRD4BRD2BRD3BRDTHDAC3
SCHEMBL4429575 0.83 KDM4E (0.55) BRD4BRD2BRD3BRDTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 BRD4 2776/4885BRD2 4008/4885BRD3 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.